SCHEMBL6867090

SCHEMBL6867090

NCc1cc(Cl)cc(Cl)c1.O=C(NCc1cc(Cl)cc(Cl)c1)c1ccccc1-c1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 2/20 0.64
CHRNA4 P43681 2/20 0.64
CHRNB4 P30926 1/20 0.64
CHRNA3 P32297 1/20 0.64
HTT P42858 2/20 0.54
KMT2A Q03164 1/20 0.54
LMNA P02545 2/20 0.50
NPSR1 Q6W5P4 1/20 0.50
HDAC7 Q8WUI4 2/20 0.49
KLKB1 P03952 3/20 0.47
KLK1 P06870 3/20 0.47
ACLY P53396 2/20 0.47
HDAC1 Q13547 1/20 0.47
CFD P00746 1/20 0.47
TAS1R3 Q7RTX0 1/20 0.46
TAS1R1 Q7RTX1 1/20 0.46
TACR1 P25103 1/20 0.46
CNR2 P34972 1/20 0.45
GAA P10253 1/20 0.45
HPGD P15428 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6871367 0.85 CHRNB2 (0.45) CHRNB2CHRNA4CHRNB4CHRNA3KMT2A
SCHEMBL6869800 0.78 CHRNB2 (0.50) CHRNB2CHRNA4CHRNB4CHRNA3HTT
SCHEMBL6016419 0.78 LMNA (0.55) HTTKMT2ALMNANPSR1KLKB1
SCHEMBL6871977 0.78 TACR1 (0.54) CHRNB2CHRNA4CHRNB4CHRNA3HTT
SCHEMBL6016439 0.77 THRB (0.53) KMT2ALMNAKLKB1KLK1TACR1
SCHEMBL19141713 0.76 CHRNB2 (0.76) CHRNB2CHRNA4CHRNB4CHRNA3HTT
SCHEMBL6397219 0.75 CHRNB2 (0.74) CHRNB2CHRNA4CHRNB4CHRNA3HTT
SCHEMBL6866336 0.74 CHRNB2 (0.68) CHRNB2CHRNA4CHRNB4CHRNA3HTT
SCHEMBL6016379 0.74 THRB (0.49) KMT2ALMNAKLKB1KLK1TACR1
SCHEMBL14081432 0.74 CHRNB2 (0.71) CHRNB2CHRNA4CHRNB4CHRNA3HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1171419-B1 BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR HOFFMANN LA ROCHE (CH) 2004-12-29 EP disclosed
US-6552088-B2 2'-methyl-biphenyl-2-carboxylic acid-(3,5-bis-trifluoromethyl-benzyl)-methyl-amide, for example; treating disease related to neurokinin 1 receptor HOFFMANN-LA ROCHE INC. 2003-04-22 US disclosed
US-20020040060-A1 Biphenyl derivatives BOS MICHAEL (CA) 2002-04-04 US disclosed
EP-1171419-A1 BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR F. HOFFMANN-LA ROCHE AG (CH) 2002-01-16 EP disclosed
US-6291465-B1 Biphenyl derivatives HOFFMANN-LA ROCHE INC. 2001-09-18 US disclosed
WO-2000053572-A1 BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR F. HOFFMANN-LA ROCHE AG (CH) 2000-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020040060-A1 Biphenyl derivatives NR1H4, NR1H2, NR1H3 CHRNB2 1434/4885CHRNA4 1474/4885CHRNB4 1471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.